vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and Solid Power, Inc. (SLDP). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $3.6M, roughly 1.8× Solid Power, Inc.). On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs -18.6%). Lineage Cell Therapeutics, Inc. produced more free cash flow last quarter ($-5.3M vs $-23.0M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs -21.9%).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

Solid Energy was the largest coal mining company in New Zealand and is a state owned enterprise of the New Zealand Government.

LCTX vs SLDP — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.8× larger
LCTX
$6.6M
$3.6M
SLDP
Growing faster (revenue YoY)
LCTX
LCTX
+149.0% gap
LCTX
130.4%
-18.6%
SLDP
More free cash flow
LCTX
LCTX
$17.7M more FCF
LCTX
$-5.3M
$-23.0M
SLDP
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
-21.9%
SLDP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LCTX
LCTX
SLDP
SLDP
Revenue
$6.6M
$3.6M
Net Profit
$851.0K
Gross Margin
Operating Margin
-99.1%
-730.1%
Net Margin
12.9%
Revenue YoY
130.4%
-18.6%
Net Profit YoY
126.0%
EPS (diluted)
$0.00
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
SLDP
SLDP
Q4 25
$6.6M
$3.6M
Q3 25
$3.7M
$3.7M
Q2 25
$2.8M
$6.5M
Q1 25
$1.5M
$6.0M
Q4 24
$2.9M
$4.5M
Q3 24
$3.8M
$4.7M
Q2 24
$1.4M
$5.1M
Q1 24
$1.4M
$6.0M
Net Profit
LCTX
LCTX
SLDP
SLDP
Q4 25
$851.0K
Q3 25
$-29.8M
$-25.9M
Q2 25
$-30.5M
$-25.3M
Q1 25
$-4.1M
$-15.2M
Q4 24
$-3.3M
Q3 24
$-3.0M
$-22.4M
Q2 24
$-5.8M
$-22.3M
Q1 24
$-6.5M
$-21.2M
Gross Margin
LCTX
LCTX
SLDP
SLDP
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
LCTX
LCTX
SLDP
SLDP
Q4 25
-99.1%
-730.1%
Q3 25
-102.9%
-654.4%
Q2 25
-715.4%
-398.9%
Q1 25
-433.1%
-399.4%
Q4 24
-178.2%
-561.1%
Q3 24
-101.6%
-593.2%
Q2 24
-416.7%
-530.8%
Q1 24
-461.3%
-433.1%
Net Margin
LCTX
LCTX
SLDP
SLDP
Q4 25
12.9%
Q3 25
-809.0%
-693.1%
Q2 25
-1101.8%
-390.7%
Q1 25
-275.6%
-251.8%
Q4 24
-114.1%
Q3 24
-80.3%
-482.0%
Q2 24
-409.1%
-438.9%
Q1 24
-453.0%
-356.2%
EPS (diluted)
LCTX
LCTX
SLDP
SLDP
Q4 25
$0.00
$-0.15
Q3 25
$-0.13
$-0.14
Q2 25
$-0.13
$-0.14
Q1 25
$-0.02
$-0.08
Q4 24
$0.00
$-0.16
Q3 24
$-0.02
$-0.13
Q2 24
$-0.03
$-0.13
Q1 24
$-0.04
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
SLDP
SLDP
Cash + ST InvestmentsLiquidity on hand
$55.8M
$250.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.5M
$415.7M
Total Assets
$112.6M
$455.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
SLDP
SLDP
Q4 25
$55.8M
$250.8M
Q3 25
$40.5M
$251.2M
Q2 25
$42.3M
$230.9M
Q1 25
$47.9M
$240.9M
Q4 24
$47.8M
$118.2M
Q3 24
$32.7M
$132.0M
Q2 24
$38.5M
$140.5M
Q1 24
$43.6M
$146.6M
Stockholders' Equity
LCTX
LCTX
SLDP
SLDP
Q4 25
$44.5M
$415.7M
Q3 25
$22.0M
$381.2M
Q2 25
$48.4M
$370.6M
Q1 25
$79.0M
$397.1M
Q4 24
$78.4M
$410.3M
Q3 24
$66.2M
$439.4M
Q2 24
$68.3M
$456.8M
Q1 24
$72.4M
$479.4M
Total Assets
LCTX
LCTX
SLDP
SLDP
Q4 25
$112.6M
$455.1M
Q3 25
$89.6M
$416.1M
Q2 25
$90.8M
$398.0M
Q1 25
$111.8M
$419.4M
Q4 24
$113.2M
$448.3M
Q3 24
$96.6M
$470.9M
Q2 24
$102.8M
$492.6M
Q1 24
$108.5M
$516.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
SLDP
SLDP
Operating Cash FlowLast quarter
$-4.9M
$-18.4M
Free Cash FlowOCF − Capex
$-5.3M
$-23.0M
FCF MarginFCF / Revenue
-79.9%
-633.0%
Capex IntensityCapex / Revenue
6.0%
126.5%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M
$-83.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
SLDP
SLDP
Q4 25
$-4.9M
$-18.4M
Q3 25
$-3.6M
$-14.3M
Q2 25
$-5.5M
$-14.4M
Q1 25
$-4.9M
$-26.3M
Q4 24
$-6.3M
$-13.9M
Q3 24
$-5.8M
$-9.9M
Q2 24
$-5.2M
$-11.1M
Q1 24
$-5.8M
$-29.1M
Free Cash Flow
LCTX
LCTX
SLDP
SLDP
Q4 25
$-5.3M
$-23.0M
Q3 25
$-3.6M
$-14.8M
Q2 25
$-5.6M
$-17.1M
Q1 25
$-5.0M
$-28.6M
Q4 24
$-6.7M
$-18.6M
Q3 24
$-5.9M
$-12.6M
Q2 24
$-5.2M
$-15.5M
Q1 24
$-5.8M
$-33.1M
FCF Margin
LCTX
LCTX
SLDP
SLDP
Q4 25
-79.9%
-633.0%
Q3 25
-98.6%
-397.6%
Q2 25
-200.8%
-264.2%
Q1 25
-331.8%
-476.1%
Q4 24
-234.0%
-416.5%
Q3 24
-156.1%
-271.5%
Q2 24
-371.2%
-305.8%
Q1 24
-403.1%
-556.3%
Capex Intensity
LCTX
LCTX
SLDP
SLDP
Q4 25
6.0%
126.5%
Q3 25
0.3%
15.3%
Q2 25
0.5%
41.5%
Q1 25
6.5%
39.1%
Q4 24
12.7%
105.5%
Q3 24
3.0%
59.7%
Q2 24
3.6%
86.8%
Q1 24
2.6%
68.1%
Cash Conversion
LCTX
LCTX
SLDP
SLDP
Q4 25
-5.73×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

SLDP
SLDP

Segment breakdown not available.

Related Comparisons